Connecticut Senate Bill SB00641

Connecticut 2021 Regular Session

• Introduced: 1/28/21
• Refer: 1/28/21

Caption

An Act Requiring Manufacturers Of Brand-name Prescription Drugs To Provide Samples Of Such Drugs To Manufacturers Of Generic Prescription Drugs.

Impact

The implementation of SB00641 could significantly affect state laws governing the pharmaceutical industry, particularly in how brand-name and generic drug manufacturers interact. By requiring brand-name companies to supply samples, the bill aims to level the playing field for generic manufacturers, which may lead to a greater variety of affordable medication options for consumers. Additionally, this move might lead to potential shifts in market dynamics, encouraging further innovation and competition within the pharmaceutical sector.

Summary

SB00641 is a legislative proposal aimed at enhancing competition in the prescription drug market by mandating that manufacturers of brand-name prescription drugs provide sufficient samples of these drugs to manufacturers of generic prescription drugs. The bill was introduced to facilitate the development of generic drugs and biosimilar products by ensuring that the latter have access to necessary reference samples for their production. This initiative is expected to promote a more competitive market, ultimately benefiting consumers through lower drug prices and increased availability of alternative medication options.

Contention

While the bill has the potential to enhance competition in the drug market, it may also face pushback from brand-name drug manufacturers who could argue that providing samples could compromise their proprietary advantages or lead to financial losses. Discussions surrounding SB00641 may highlight concerns about how equitable access to drug samples will be ensured and whether there are sufficient safeguards in place to prevent misuse of the samples provided to generic manufacturers. The balance between encouraging competition and protecting intellectual property rights will be a key point of contention as the bill progresses.